The estimated Net Worth of Deyaa Adib is at least 32.8 千$ dollars as of 12 June 2024. Deyaa Adib owns over 22,123 units of FibroGen Inc stock worth over 32,849$ and over the last few years Deyaa sold FGEN stock worth over 0$.
Deyaa has made over 1 trades of the FibroGen Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Deyaa bought 22,123 units of FGEN stock worth 25,884$ on 12 June 2024.
The largest trade Deyaa's ever made was buying 22,123 units of FibroGen Inc stock on 12 June 2024 worth over 25,884$. On average, Deyaa trades about 22,123 units every 0 days since 2024. As of 12 June 2024 Deyaa still owns at least 82,123 units of FibroGen Inc stock.
You can see the complete history of Deyaa Adib stock trades at the bottom of the page.
Deyaa's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B Riggs、Thomas B Neff、Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: